Evolus, Inc.
Close on Oct 19, 2026
- Market cap
- $485.24M
- P/E (TTM)
- –
- Dividend yield
- –
About Evolus
Pharmaceutical Preparations, SIC 2834
The company operates in the medical aesthetics industry, developing and marketing non-reimbursed, cash-pay aesthetic products. Its primary offerings comprise injectable neurotoxins and hyaluronic acid dermal fillers designed to treat facial lines and folds. Specifically, it commercializes Jeuveau, an injectable botulinum toxin type A formulation for frown lines, and the Evolysse collection of hyaluronic acid gels for facial wrinkles and volume restoration. The company sells these treatments directly to licensed aesthetic practitioners who administer them to adult consumers.
The company distributes its products internationally, with commercial operations and regulatory authorizations spanning the United States, Canada, Australia, Switzerland, the United Kingdom, and members of the European Union and European Economic Area. Its neurotoxin supply is produced by a third-party partner in South Korea, while its hyaluronic acid gel line is manufactured at a facility near Lyon, France. The provided text does not state the company's headquarters location.
Summary of the business section of Evolus's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Evolus, Inc.
- Founded
- 2012
- Headquarters
- Newport Beach, CA
- Address
- 520 Newport Center Drive, Suite 1200 92660
- Phone
- (949) 284-4555
- Website
- evolus.com
- Employees
- 334, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Irvine, California
Stock & identifiers
- Ticker
- EOLS
- Exchange
- Nasdaq
- IPO date
- Feb 9, 2018
- Shares outstanding
- 66M, Jul 31, 2026
- Public float
- $560.40M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1570562
- CUSIP
- 30052C107
- ISIN
- US30052C1071
- LEI
- 549300VYQRYBQOT8V419
- EIN
- 46-1385614
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Moatazedi | See Remarks, Director | 499,592 |
| Rui Avelar | See Remarks | 427,423 |
| Tatjana Mitchell | Chief Financial Officer | 226,092 |
| Tomoko Yamagishi-Dressler | Chief Marketing Officer | 89,949 |
| Sandra Beaver | Chief Financial Officer | 167,089 |
| Karah Herdman Parschauer | Director | 77,742 |
| Brady Stewart | Director | 134,188 |
| Albert G. White III | Director | 95,937 |
| David N. Gill | Director | 86,887 |
| Vikram Malik | Director | 321,109 |
| Simone Blank | Director | 559,894 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Moatazedi | $6.41M | -$746.49K | $2.04M | $102 | $120 |
| FY2024 Mr. Moatazedi | $7.00M | $4.81M | $2.09M | $170 | $91 |
| FY2023 Mr. Moatazedi | $11.24M | $13.56M | $2.69M | $162 | $92 |
| FY2022 Mr. Moatazedi | $3.60M | $5.82M | $1.51M | $115 | $90 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 334 employees, all of whom were full-time in the United States, Canada, Europe, and Australia, and 67% of our full-time employees were women.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 12, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 9, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 1, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |